Causeway is delighted to announce the completion of a £8.75 million investment. The round was led by Declan Doogan (our Executive Chairman) along with Scottish Investment Bank, MediqVentures, Lennox Capital and the University of Glasgow. This funding will allow us to continue TenoMiR’s development for the treatment of tendinopathy, building on the positive trial data from our Phase 1b, which appeared safe and well tolerated. TenoMiR also showed encouraging signs of efficacy- improving pain and function in patients with Lateral epicondylitis (tennis elbow). Strikingly, TenoMiR also showed unprecedented improvement in tendon structure. A Phase 2 study in the USA, The Netherlands and the UK will begin recruiting in September 2023.